This article was originally published in The Gray Sheet
Executive SummaryRaises $6 mil. in private placement of common stock and warrants for "general corporate purposes." The San Francisco firm, which makes electron beam tomography (EBT) scanners, notes that the financing "is important for Imatron to enable us to continue to increase our sales coverage and to expand our marketing initiatives"
You may also be interested in...
Cadila has filed for approval of saroglitazar for NASH in India. The drug, which could emerge as the first medicine for the indication if approved, is already being used by a million Indian patients for diabetic dyslipidemia and hypertriglyceridemia.
It has been a long and sometimes tortuous development path for Lupuzor but ImmuPharma's chief executive tells Scrip the company's faith in the lupus drug is bearing fruit.
The EU network of health technology assessment bodies says it is seeing the benefit of systematically involving patients when companies approach it for early scientific advice on evidence generation.